GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

JW Pharmaceutical 001060.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

22,850

+1.11%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩775.30bn

FY2016FY2025

Net income

₩61.51bn

FY2016FY2025

Free cash flow

₩60.28bn

FY2016FY2025

Shareholders' equity

₩369.37bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩775.30bn₩719.38bn₩748.53bn₩684.35bn₩606.58bn₩547.34bn₩511.34bn₩537.18bn₩502.92bn₩467.47bn
Gross profit₩359.31bn₩323.50bn₩335.54bn₩287.95bn₩234.38bn₩177.53bn₩161.12bn₩197.04bn₩188.63bn₩173.34bn
Research and development₩45.45bn₩36.24bn₩33.67bn₩33.74bn₩19.88bn₩22.94bn₩25.22bn₩21.27bn₩21.98bn₩18.00bn
Operating income₩94.46bn₩82.73bn₩60.11bn₩62.78bn₩31.20bn−₩1.32bn−₩20.65bn₩21.58bn₩21.72bn₩24.54bn
Net income₩61.51bn₩65.04bn₩37.01bn₩31.89bn−₩967.8m−₩15.24bn−₩25.28bn₩8.06bn−₩742.5m−₩10.93bn
Diluted earnings per share2,888.963,054.701,738.061,497.84-45.46-715.83-1,187.08394.38-33.41-327.34

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩605.27bn₩604.60bn₩645.04bn₩627.97bn₩633.05bn₩549.09bn₩573.21bn₩593.79bn₩630.87bn₩651.08bn
Total liabilities₩235.90bn₩275.11bn₩379.60bn₩402.21bn₩444.51bn₩341.62bn₩343.12bn₩333.68bn₩360.10bn₩374.76bn
Debt—₩25.10bn₩30.00bn—₩120.74bn₩73.58bn₩185.14bn₩175.22bn₩190.36bn₩212.41bn
Shareholders' equity₩369.37bn₩329.49bn₩265.44bn₩240.35bn₩201.19bn₩207.49bn₩230.08bn₩260.11bn₩270.78bn₩276.31bn
Shares outstanding21m21m21m21m21m21m21m20m22m33m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩96.40bn₩79.39bn₩87.16bn₩56.76bn₩18.12bn₩63.05bn₩55.53bn₩52.11bn₩33.45bn₩6.74bn
Capital spending−₩36.12bn−₩28.14bn−₩40.71bn−₩9.92bn−₩7.47bn−₩12.39bn−₩9.28bn−₩8.64bn−₩7.50bn−₩10.02bn
Free cash flow₩60.28bn₩51.25bn₩46.45bn₩46.85bn₩10.66bn₩50.67bn₩46.25bn₩43.47bn₩25.95bn−₩3.28bn
Dividends paid−₩11.07bn−₩9.67bn−₩8.81bn−₩7.35bn−₩7.15bn−₩6.95bn−₩6.82bn−₩6.51bn−₩5.88bn−₩2.71bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩222.02bn₩199.88bn₩198.94bn₩200.02bn₩191.10bn₩185.24bn₩187.85bn₩178.66bn
Gross profit₩105.29bn₩98.46bn₩89.85bn₩94.63bn₩90.66bn₩84.18bn₩82.99bn₩86.36bn
Operating income₩34.98bn₩33.58bn₩15.46bn₩32.03bn₩24.97bn₩23.70bn₩19.93bn₩27.45bn
Net income₩27.89bn₩27.48bn₩15.32bn₩30.59bn−₩1.87bn₩17.47bn₩16.59bn₩19.85bn
Diluted earnings per share1,309.971,290.80719.421,436.62-87.61820.53779.39932.13
Cash from operations₩42.51bn₩17.50bn₩27.55bn₩46.91bn−₩6.65bn₩28.58bn₩18.95bn₩10.83bn
Capital spending−₩4.52bn−₩6.57bn−₩13.49bn−₩9.79bn−₩4.58bn−₩8.26bn−₩7.99bn−₩9.36bn
Free cash flow₩37.98bn₩10.93bn₩14.06bn₩37.12bn−₩11.23bn₩20.32bn₩10.96bn₩1.48bn
Total assets₩659.89bn₩621.61bn₩605.27bn₩611.56bn₩590.08bn₩611.04bn₩604.60bn₩636.88bn
Debt—————₩25.10bn₩25.10bn₩27.50bn
Shareholders' equity₩409.94bn₩381.78bn₩369.37bn₩354.10bn₩323.28bn₩331.09bn₩329.49bn₩303.77bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.2%7.2%6.0%
Operating income14.6%—15.9%
Net income24.5%—41.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin45.7%44.6%42.1%39.8%
Operating margin11.9%10.3%8.1%6.1%
Net margin8.5%6.7%4.4%2.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings8.87.920.412.4-491.7-46.6-23.092.7-1192.7-138.8
Price to sales0.70.71.00.60.81.31.11.41.83.3

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 31 Mar 2026.

FY2026FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year650.00450.00400.00666.286291.589291.589283.096234.846
  • 1.02-for-1 split · 27 Dec 2023
  • 103-for-100 split · 29 Dec 2021
  • 1.03-for-1 split · 29 Dec 2020
  • 1.03-for-1 split · 27 Dec 2019
  • 1.02-for-1 split · 27 Dec 2018
  • 1.02-for-1 split · 27 Dec 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.